The LICR holds the world’s foremost portfolio of tumor antigen patents and their flagship antigen, NY-ESO-1, licensed to Serametrix as part of this agreement, has already shown promise as a predictor of drug response. It was also announced that Serametrix will add to its current array-based services by launching a serum profiling service dedicated solely to NY-ESO-1 antibody detection. This test will have immediate application in the clinical development of novel cancer therapies.
As part of the deal LICR will take an equity stake in Serametrix. In another significant move, Director of LICR’s New York Branch, Dr Lloyd Old, was appointed Chairman of the Serametrix Scientific Advisory Board. In a statement, Dr Lloyd Old said “Immunological monitoring has a vital role to play in cancer therapy. Tumor antigens have already proved valuable as drug targets and this new agreement will ensure they are also exploited as biomarkers for predicting drug response”.
Dr. Henry Hepburne-Scott, Chief Executive Officer of Serametrix added: “Serametrix is pleased to build upon its relationship with the LICR, whose leadership position in tumor immunology is beyond question. This alliance of world-class research with commercial enterprise represents a significant step towards more targeted cancer treatments”.
Financial details of the agreement were not disclosed.
Serametrix uses proprietary technologies across multiple platforms to discover and to validate autoantibody biomarker panels that have utility in drug development and clinical applications. In addition to in-house research, Serametrix partners with major institutions and pharmaceutical companies from around the world. By combining the knowledge base of best-in-class researchers and clinicians, Serametrix is able to provide a more rational approach to patient treatment.
LICR is a global non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery employing over 800 scientists in Branches throughout North and South America, Europe and Australia. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, LICR is actively engaged in translating its discoveries into applications for human benefit.
Dr. Andrew Simpson, Scientific Director